Fortress Biotech (FBIO) vs vTv Therapeutics (VTVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fortress Biotech (FBIO) has outperformed vTv Therapeutics (VTVT) over the past year, losing 26.6% versus a loss of 47.5%. Over five years, VTVT leads with a -71.1% price change compared with -95.5% for FBIO. Fortress Biotech is the larger company by market cap ($64.1 million vs $62.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBIO | VTVT |
|---|---|---|
| Share price | $1.90 | $15.51 |
| Market cap | $64.11M | $62.22M |
| 1-day change | +7.34% | -5.20% |
| YTD return | -48.09% | -61.22% |
| 1-year return | -26.64% | -47.53% |
| 5-year return | -95.52% | -71.06% |
| P/E ratio (TTM) | 0.83 | — |
| EPS (TTM) | $2.30 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $63.26M | $0 |
| Revenue growth (YoY) | +9.69% | -100.00% |
| Net income (latest FY) | $6.82M | $-26.97M |
| Gross margin | 66.92% | — |
| Operating margin | -111.00% | — |
| Net margin | 10.77% | — |
| 52-week high | $4.53 | $44.00 |
| 52-week low | $1.64 | $15.47 |
| Distance from 52-week high | -58.06% | -64.75% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +163.16% | +261.06% |
| Average volume | 281.49K | 33.07K |
| Shares outstanding | 33.74M | 4.01M |
| Employees | 78 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FBIO has outperformed VTVT by 20.9 percentage points over the past year.
- Fortress Biotech grew revenue faster in its latest fiscal year (+9.69% vs -100.00%).
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees
About vTv Therapeutics
VTVT stock →vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
FBIO vs VTVT FAQ
Which is bigger, Fortress Biotech or vTv Therapeutics?
Fortress Biotech (FBIO) is larger, with a market capitalization of $64.11M compared with $62.22M for vTv Therapeutics (VTVT).
Which stock has performed better over the past year, FBIO or VTVT?
FBIO returned -26.64% over the past 12 months, compared with -47.53% for VTVT (price return, excluding dividends). Past performance does not predict future results.
Are Fortress Biotech and vTv Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.